Theoretically, agents that increase or prolong cAMP levels, such as PDE inhibitors that are beneficial in experimental models of MS and/or are currently used in clinical trials [194,195,196,197], may overcome Fn-mediated inhibition of OPC differentiation, and thus, benefit remyelination. Here, FN1 is linked to myeloid sarcoma.